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Abstract Nitric oxide plays an important role in the
pathogenesis of migraine as well as tension-type headache.
Studies suggest that the expression of molecules involved
in the pathogenesis of headache, i.e., nitric oxide and
interleukin, is influenced by apolipoprotein E (APOE)
and is gene specific. Hence, we hypothesized that APOE
polymorphism may be associated with migraine as well as
tension-type headache.The study sample comprised of
three groups: migraineurs, tension-type headache subjects
as well as a healthy control group. A total of 50 subjects in
each group were included after screening for the inclusion
and exclusion criteria. None of the subjects was a blood
relative of any other subject included in the present study.
Their venous blood was drawn and stored at -20C.
Genomic DNA extraction was performed with a commer-
cial kit and simple sequence-specific primer PCR was
performed to assess the APOE polymorphism. Data were
analyzed with the help of SPSS V11.0 for Windows. v2 test
and logistic regression analysis were run. The results of the
study showed that APOE e2 gene increases the risk of
migraine as compared to the control group and the tension-
type headache group (OR = 4.85; 95% CI = 1.92–12.72;
P \ 0.001 and OR = 2.31; 95% CI = 1.08–4.94; P =
0.01, respectively). Interestingly, APOE e4 gene was pro-
tective against migraine as well as tension-type headache.
This study shows that APOE e2 gene increases the risk of
migraine, while APOE e4 gene is protective against
migraine and tension-type headache. Further research is
required to confirm the findings of the present study in a
larger sample and to elucidate the role of APOE poly-
morphism in headache.
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Introduction
Nitric oxide (NO) is thought to play a central role in the
pathogenesis of migraine as well as tension-type headache.
Up-regulation of the endogenous L-arginine/NO pathway
and increased NOS expression (perhaps the constitutive
form) have been hypothesized in migraineurs during spon-
taneous migraine attacks [1]. Whether this up-regulation is
expressed only at the endothelial level or also occurs at the
neural level, especially in the pain transmission path-
ways, has been a matter of controversy among headache
researchers [2]. There is evidence that trigeminal neurons
contain nitric oxide and its activity is regulated by nNOS, as
suggested by the increase in c-fos immunoreactivity of tri-
geminal nucleus caudalis following administration of nitrate
donor [3]. Furthermore L-NAME, a nitric oxide synthatase
inhibitor, can reduce this activity [4].
Nitric oxide has its role not only in the development of
migraine, but also in the pathogenesis of tension-type
headache [5]. It is suggested that nitroglycerin increases the
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pre-existing central sensitization in chronic tension-type
subjects, and nitric oxide synthetase inhibitors are helpful
in the management of chronic tension-type headache by
reducing the central sensitization [5].
Besides nitric oxide synthetase, nitric oxide production is
also dependent on apolipoprotein E (APOE) polymorphism
and this production is gene specific [6]. Available literature
suggests that APOE e4 increases the uptake of arginine in
microglia as compared to APOE e3 and thus may regulate
production of nitric oxide [6]. Relatively increased nitric
oxide production has been reported by APOE e4 containing
monocytes as compared to the monocytes harbouring
APOE e3 gene [7]. This production is independent of the
expression of iNOS gene and may be largely dependent on
the arginine uptake [6]. The increased production of NO is
consistent with the increased nitrative/oxidative stress
observed with APOE e4 and may underlie the greater neu-
ronal damage seen after closed head injury and stroke [7].
The production of nitric oxide may be gender dependent, as
monocytes from APOE e4/e4 male transgenic mice have
been shown to produce more nitric oxide as compared to
APOE e3/e3 mice. However, this difference was not
observed in female APOE transgenic mice [8]. Not only the
gender, but also the amount and isoform of APOE might
influence the development of inflammation. Higher
inflammation activity was associated with the APOE e4
gene as compared to the APOE e3 gene [9].
Similarly, APOE polymorphism also influences the
expression of the cytokines that are commonly involved in
migraine and tension-type headache [10, 11]. APOE e3
gene containing cells have lower expression of cytokines
TNF-a and IL-6 as compared to cells expressing APOE e2
and APOE e4 genes [11]. Moreover, circulating IL-10
levels are also dependent on the presence of APOE e4 gene
[12].
Based on these evidences, we hypothesized that APOE
gene polymorphism should be associated with migraine
and TTH. The present study was planned to assess the role
of APOE gene polymorphism in migraine as well as TTH
patients.
Method
A total of 50 subjects suffering from migraine, 50 subjects
with tension-type headache and 50 controls were recruited
from the headache clinic of a teaching hospital according
to convenient sampling. The study was approved by the
institutional ethics committee and informed consent was
obtained from all the study subjects. Migraine and TTH
were diagnosed according to the International Classifica-
tion of Headache Disorders (ICHD-2) criteria [13]. The
control group consisted of subjects who never had recurrent
primary headaches and in whom family history was neg-
ative for primary headaches. All the participants belonged
to the same ethnic group and had comparable socio-eco-
nomic status. None of the subjects were genetically related
to the other subject included in the study.
All the subjects were screened for the exclusion criteria
and if present, then that subject was excluded from the
study. Subjects with the following were excluded from the
study:.major neurological disorders, e.g., epilepsy, space
occupying lesions , neurodegenerative disorders, chronic
daily headache (undiagnosed or mixed type), substance use
disorders (except tobacco), those taking prophylactic drugs
for migraine or tension-type headache for more than
3 weeks, those with co-morbid other primary headache or
co-morbid psychiatric disorder, and those consuming anti-
oxidants or multivitamins for more than 1 week.
Patient’s history of headache was taken in detail, fol-
lowed by the clinical examination and, wherever required,
appropriate laboratory investigation to rule out secondary
headache. Parallel information was also collected from
a reliable family member regarding headaches of the
sufferer. All the information was recorded on a semi-
structured performa.
Genotyping
In a sterile EDTA vacutainer, 3 ml venous blood was
collected, at least 3 days after the attack of headache and
immediately stored at -20C. Genomic DNA was extrac-
ted with the help of Himedia Pura(R) kit, based on the spin-
column technique to provide 4–20 lg of genomic DNA
from 200 lL of human blood.
DNA samples were subjected to polymerase chain
reaction according to the method described by Pantelidis
et al. [14] with slight modifications. This method involved
use of four primers, which were combined to form three
sets, each set containing two primers to detect the presence
of a given allele of the APOE gene. Because this geno-
typing system is based on the presence or absence of PCR
amplification by allele-specific primers, it is imperative to
ensure PCR amplification for those reactions that do not
produce allele-specific amplicons. For this reason, each
APOE-specific primer mix also contained a pair of ‘‘con-
trol primers’’ (primers 8 and 9), which amplified two
regions of chromosome 6 in the HLA-DR locus, to verify
PCR amplification in the absence of haplotype-specific
amplification in each PCR reaction.
Amplification was performed in a thermal cycler
(Appendorf) using a high stringency PCR protocol with
high annealing temperature to ensure specificity of ampli-
fication. The conditions were as follows: initial
denaturation for 1 min at 96C, followed by 5 cycles of
20 s at 96C, 45 s at 70C and 25 s at 72C; 21 cycles of
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25 s at 96C, 50 s at 65C and 30 s at 72C; 4 cycles of
30 s at 96C, 60 s at 55C and 120 s at 72C.
The PCR products were analyzed by electrophoresis on
a 1.5% Tris–borate-EDTA/editium bromide agarose gel
with 1 lL of loading dye at 6–8 V/cm. For all PCR reac-
tions (APOE e2, APOE e3, and APOE e4), the presence of
a 173-bp band indicated the presence of the specific APOE
gene and a band at 785 bp depicted the product of the
control gene.
Statistical analysis
Statistical analysis was done with the help of SPSS v 11.0
for Windows. For the categorical variables, v2 test was run.
Binary logistic regression was applied to calculate the odds.
The results were considered to be significant when P value
was less than 0.05. The power of the study was calculated
using Ca-TS software (http://csg.sph.umich.edu/) and
deviation from Hardy–Weinberg equilibrium (HWE) was
calculated manually.
Results
Composition of study sample
All the three study groups were identical with respect to
average age (27.66 years among migraineurs; TTH group
27.6 years; control group 25.18 years). Both the headache
groups had preponderance of females (82% among
migraineurs; 100% in TTH group; 25% in control group
v2 = 70.59, P \ 0.001).
When illness-related factors were analyzed, it was found
that the migraine and tension-type headache groups did not
differ with regard to the total duration of illness, duration
since the illness became disabling and the duration of the
individual headache episodes.
In the migraine subgroup, 76% of the subjects had
migraine without aura; 12% had migraine with aura and the
rest had headache of both types. In the tension-type
headache group, 56% suffered from chronic headache,
while in the remaining group, headache was episodic.
Family history of primary headache was reported by 26%
of migraineurs versus 14% of TTH subjects (v2 = 2.11;
P = 0.34). However, due to recall bias the exact diagnosis
was not made. None of the subjects in the control group
had a family history of primary headache, as such cases
were excluded from the study.
Distribution of genes and genotypes
Distribution of APOE genes in the sample is shown in
Table 1. Genotypes APOE e2/e2 and APOEe2/e3 were
most frequent among migraineurs, whereas APOE e3/e3
was the most prevalent genotype in tension-type headache
followed by APOE e3/e4 and APOE e2/e4. The control
group had the highest frequency of APOE e3/e4 genotype
followed by APOE e3/e3. The detailed distribution is
depicted in Table 2.
Odds to develop headache
Results show that APOE e2 gene increases the odds of
developing migraine to nearly five times (95% CI = 1.92–
12.72; P \ 0.001) as compared to controls. However,
APOE e4 gene was protective for migraine as well as TTH
(OR = 0.53; 95% CI = 0.28–0.98; P = 0.01 for both
groups). Other genes did not have any effect on the
migraine or the tension-type headache.
When tension-type headache group is taken as a refer-
ence category, APOE e2 gene was found to increase the
odds of migraine by 2.31 (95% CI = 1.08–4.94; P = 0.01).
The other gene did not show any effect.
Testing of the power of the study and deviation
from Hardy–Weinberg equilibrium
Power analysis shows that considering the prevalence of
migraine close to 15%, a = 0.05 and other data from
Table 1, the power of the present study is 85% in the
single-stage additive model.
Testing for Hardy–Weinberg equilibrium showed that
all the three groups deviated significantly from the equi-
librium (migraine v2 = 25.52, df = 3, P \ 0.001; TTH
Table 1 APOE allelic frequencies (%) in the study subjects (N = 50
in each group)
Group APOE e2 APOE e3 APOE e4
Migraine 24 (16) 53 (35) 23 (16)
TTH 12 (11) 65 (38) 23 (20)
Controls 6 (6) 58 (40) 36 (32)
The number of subjects is given in parentheses









APOE e2/e2 8 (0.16) 1 (0.02) –
APOE e2/e3 8 (0.16) 2 (0.04) –
APOE e2/e4 – 8 (0.16) 6 (0.12)
APOE e3/e3 18 (0.36) 27 (0.54) 18 (0.36)
APOE e3/e4 9 (0.18) 9 (0.18) 22 (0.44)
APOE e4/e4 7 (0.14) 3 (0.06) 4 (0.08)
The percentage of subjects is given in parentheses
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v2 = 18.44, df = 3, P \ 0.001; and control group v2 =
11.68, df = 3, P \ 0.01).
Discussion
In short, the present study revealed that APOE e2 gene
increased the odds in favor of migraine. A very interesting
and surprising finding of the study was the protective effect
offered by APOE e4 gene. At least one study in the past
attempted to find out the effect of APOE polymorphism on
the risk of migraine, but they did not find any particular
association [15]. However, it must be noted that subjects in
that study had mixed headache, i.e., migraine as well as
tension-type headache.
It was surprising to find the protective effects of APOE
e4 gene, since it increases the microglial nitric oxide pro-
duction. Though direct studies addressing the issue of
microglial involvement in migraine are not available, we
could find two studies that hypothesized that microglial
nitric oxide production might be important in migraine [16,
17]. Contrary to this hypothesis, results of the present study
suggest that nitric oxide generated during migraine and
tension-type headache is probably independent of the
microglial nitric oxide production, which is increased by
the presence of APOE e4 in the microglia as reported
by Colton et al. [7].
The microglia also comes into light when we see that
cytokines also play their role in primary headaches [10].
Pro-inflammatory and anti-inflammatory cytokines show
different relationships with the migraine attack. Perini et al.
[11] found that TNF-a levels were increased during
migraine attacks and they quantitatively correlated with the
time elapsed after the headache onset. Similarly, levels of
IL-1b also elevate during migraine, but that of other pro-
inflammatory cytokines IL-2 and IL-6 remain unchanged.
Not only pro-inflammatory, but also the anti-inflammatory
cytokine, e.g., IL-10, increases during headache, especially
soon after attack; however, the level of IL-4 remains
unchanged. Increase in IL-6 in serum was demonstrated in
two studies within 1 h of initiation of migraine attack [18,
19]. Furthermore, microglial cytokines are also influenced
by APOE polymorphism and, together, these reports
deduce that APOE e3 gene could be protective and APOE
e4 might predispose to migraine [11, 12, 20–22], which
was not seen in the present study.
It is known that APOE e2 lessens the amount of pro-
inflammatory cytokine production from microglia, while
APOE e3 and APOE e4 increase it linearly [20]. APOE e4
increases the release of IL-1b, PGE2 as well as TNF-a and
IL-6 [21, 22]. Hence, APOE e4 predisposes the person to
suffer a sustained inflammatory response both in the central
nervous system as well as in the rest of the body [22, 23].
This inflammatory response usually manifests as gliosis in
the central nervous system. However, neuro-imaging
studies of the brain in subjects suffering from migraine
failed to show any such findings [24], and this further
supports our results. This also suggests that the increase in
pro-inflammatory cytokines (TNF-a and IL-1b) in migrai-
neurs may not be related to the APOE genotypes, and this
increase probably represents an epi-phenomenon secondary
to the increased CGRP [10]. Another possibility remains
that similar to the case of nitric oxide discussed above,
these cytokines are perhaps not generated from the
microglia during these headaches. As seen in the migraine
cases, structural neuroimaging studies of tension-type
headache patients also do not show any evidence of gliosis,
and neither was increased cytokines reported in their blood
during headache [18]. The observed increment of IL-6 in
TTH patients was ascribed to the psychological stress
rather than to the pathology itself [19].
Akin to this study, previous studies also failed to find the
association linkage of polymorphisms of various genes
including neuronal NOS [25], inducible NOS [26], dopa-
mine transporter gene [27] and interleukin-6 gene [28] with
the migraine or its subtypes, probably owing to the heter-
ogenicity of the migraine.
Like any other study, this study also had some limitations.
Migraine and TTH are frequently co-existent with other ill-
nesses, e.g., depression, anxiety, allergies, etc., and also with
each other [29]. Hence, it was difficult to identify and recruit
subjects with pure migraine as well as isolated tension-type
headache. The rigorous exclusion increases the validity of
our findings, but at the cost of limiting the sample size.
Moreover, as already mentioned, the power of the present
study is 85% in the single-stage additive model. Hence, the
results of the study are important and valid. Secondly, in this
study, we excluded subjects with active coronary artery
disease, hypertension and focal neurological deficit, which
could be a bias against our finding. However, reports suggest
that the prevalence of APOE e4 gene is otherwise low in
India [30, 31]. A recent review suggests that the absolute risk
for ischemic vascular events in migraineurs, thought to be
predisposed by the presence of APOE e4 gene, is also low
[32–34]. Thirdly, the effect of gene doses was not taken into
consideration during the present study owing to the small
number of genotypes analyzed in each group. This has shown
associations with other disease markers, particularly brain
atrophy in a few, but not all, studies [35–37]. Hence, its
significance is still debatable, but it is an interesting area and
may be explored in future studies. Fourth, the genotype
distribution in all groups, especially control group, was
deviant from the Hardy–Weinberg equilibrium. Deviation
from the Hardy–Weinberg equilibrium is considered to be a
measure of genotyping error, stratification or inbreeding.
However, a recent study finds that deviation from HWE is not
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consistent with genotyping error [38]. In addition, another
study suggested that any data set showing deviation from the
HWE should not be discarded as it may mask an important
and causal polymorphism [39]. Moreover, our data is con-
sistent with the frequencies of APOE genes described in
previous studies [40–42]. The deviation in the present study
is due to the absence of gene in the control group that has
been attributed as being causative. Though we cannot rule
out the errors due to small sample size, looking at the power
of the study, the present findings appear true.
In conclusion, the present study shows that APOE e2
gene increases the risk of migraine. This is theoretically
unexpected and a new finding. This finding requires con-
firmation in a population-based study. Also, further
research is required to elucidate the pathophysiological role
of APOE gene polymorphism and microglia in migraine.
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